ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

direclidine

Also written as “NBI-1117568”, “HTL0016878” and “HTL0016878.HCl Solution 10 mg”.

Its studies are mostly in Schizophrenia · Mania, led by 2 companies.

Drug pageDireclidine: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 30, 20259 company-led studies, 5 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciencesits history only65 open or runningphase 3since Apr 30, 2025Sep 14, 2022Oct 2027phase 3 · NCT06963034
Nxera Pharma UK30 open or runningphase 1since Aug 3, 2017Aug 3, 2017none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nxera Pharma UK only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2017First study: phase 1 study in HealthyFirst studyNCT03244228 · 120 enrolled · United Kingdom
  2. Apr 15, 2021Phase 1 study in Healthy SubjectsNCT04849286 · 16 enrolled · United Kingdom
  3. Jun 21, 2021Phase 1 study in Healthy SubjectsNCT04935320 · 15 enrolled · United Kingdom
  4. Aug 11, 2024Named direclidineINNProposed as its International Nonproprietary Name in WHO's List 131 · before, NBI-1117568, HTL0016878

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Nxera Pharma UK leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04935320Healthy Subjects · United Kingdom1CompletedOct 29, 202115
NCT04849286Healthy Subjects · United Kingdom1CompletedDec 7, 201816
NCT03244228Healthy · United Kingdom1CompletedSep 23, 2019120

How it is read

Names in the registry

  • “NBI-1117568”, 6 entries
  • “HTL0016878”, 2 entries
  • “HTL0016878.HCl Solution 10 mg”, 1 entry
  • “HTL0016878.Citrate Capsule 10 mg”, 1 entry

Codes read as this program: HTL0016878.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.